Upcoming drugs for the treatment of preeclampsia in pregnant women

References

• Fenton C, Hobson SR, Wallace EM, Lim R. Future therapies for pre-eclampsia: beyond treading water. Aust N Z J Obstet Gynaecol 2014;54(1):3-8
   PubMed Web of Science ®Google Scholar
• Everett TR, Wilkinson IB, Lees CC. Drug development in preeclampsia: a ’no go’ area? J Matern Fetal Neonatal Med 2012;25(1):50-2
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent I, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta 2014;35:5.11
   Web of Science ®Google Scholar
• Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig 2004;11(6):342-52
   PubMedGoogle Scholar
• Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology(Bethesda) 2009;24:147-58
   Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
   PubMed Web of Science ®Google Scholar
• George EM, Palei AC, Granger JP. Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. Curr Opin Nephrol Hypertens 2012;21(2):157-62
   PubMed Web of Science ®Google Scholar
• Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007;2(3):543-9
   PubMed Web of Science ®Google Scholar
• Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res 2011;127(3):70020-2
   Google Scholar
• Nakamura M, Sekizawa A, Purwosunu Y, et al. Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. Prenat Diagn 2009;29(7):691-6
   PubMed Web of Science ®Google Scholar
• Ornaghi S, Barnhart KT, Frieling J, et al. Clinical syndromes associated with acquired antithrombin deficiency via microvascular leakage and the related risk of thrombosisThromb Res 2014;133(6):972-84
   PubMed Web of Science ®Google Scholar
• Paidas MJ, Sibai B, Triche EW, et al. Exploring the role of antithrombin replacement for the treatment of preeclampsia: a prospective randomized evaluation of the safety and efficacy of recombinant antithrombin in very preterm preeclampsia (PRESERVE-1). Am J Reprod Immunol 2013;69(6):539-44
   PubMed Web of Science ®Google Scholar
• PRESERVE-1 trial. Available from: http://clinicaltrials.gov/show/NCT02059135
   Google Scholar
• Wang J, Mimuro S, Lahoud R, et al. Elevated levels of lipoprotein(a) in women with preeclampsia. Am J Obstet Gynecol 1998;178(1 Pt 1):146-9
   PubMed Web of Science ®Google Scholar
• Potter JM, Nestel PJ. The hyperlipidemia of pregnancy in normal and complicated pregnancies. Am J Obstet Gynecol 1979;133(2):165-70
   PubMed Web of Science ®Google Scholar
• Wang Y, Wally A, Schulze A, et al. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus Apher Sci 2006;35(2):103-10
   PubMed Web of Science ®Google Scholar
• Blessing F, Wang Y, Nagel D, Seidel D. The efficacy and safety of the new heparin-induced extracorporeal low-density lipoprotein precipitation system (Plasmat Futura) in comparison with the currently used system (Plasmat Secura). Ther Apher Dial 2014;8(1):33-8
   Google Scholar
• Saad AF, Kechichian T, Yin H, et al. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci 2014;21(1):138-45
   PubMed Web of Science ®Google Scholar
• Carver AR, Tamayo E, Perez-Polo JR, et al. The effect of maternal pravastatin therapy on adverse sensorimotor outcomes of the offspring in a murine model of preeclampsia. Int J Dev Neurosci 2014;33:33-40
   PubMed Web of Science ®Google Scholar
• McDonnold M, Tamayo E, Kechichian T, et al. The effect of prenatal pravastatin treatment on altered fetal programming of postnatal growth and metabolic function in a preeclampsia-like murine model. Am J Obstet Gynecol 2014;210(6):542.e1-7
   Web of Science ®Google Scholar
• Nanovskaya TN, Patrkeeva S, Paul J, et al. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol 2013;209(4):038
   PubMed Web of Science ®Google Scholar
• Costantine MM, Cleary K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013;121(2 Pt 1):349-53
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01717586
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01278459?displayxml=true
   Google Scholar
• Seidel D, Armstrong VW, Schuff-Werner P. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. HELP Study Group. Eur J Clin Invest 1991;21(4):375-83
   PubMed Web of Science ®Google Scholar
• Wang Y, Blessing F, Walli AK, et al. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins – reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004;175(1):145-50
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01967355
   Google Scholar
• Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124(8):940-50
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01404910
   Google Scholar
• Teichman SL, Unemori E, Teerlink JR, et al. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7(2):75-82
   PubMedGoogle Scholar
• EudraCT Number 2011-001617-14. Available from: www.clinicaltrials.gov/ct2/show/NCT01566630
   Google Scholar
• Unemori E, Sibai B, Teichman SL. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann N Y Acad Sci 2009;1160:381-4
   Google Scholar
• Adair CD, Luper A, Rose JC, et al. The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind, randomized, clinical trial. J Perinatol 2009;29(4):284-9
   PubMed Web of Science ®Google Scholar
• Lam GK, Hopoate-Sitake M, Adair CD, et al. Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor: a secondary analysis of the DEEP Trial. Am J Obstet Gynecol 2013;209(2):10
   Web of Science ®Google Scholar
• Johal T, Lees CC, Everett TR, Wilkinson IB. The nitric oxide pathway and possible therapeutic options in pre-eclampsia. Br J Clin Pharmacol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Manzur-Verastegui S, Mandeville P, Gordillo-Moscoso A, et al. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol 2008;35(5-6):580-5
   PubMed Web of Science ®Google Scholar
• Trapani A Jr, Goncalves LF, Pires MM. Transdermal nitroglycerin in patients with severe pre-eclampsia with placental insufficiency: effect on uterine, umbilical and fetal middle cerebral artery resistance indices. Ultrasound Obstet Gynecol 2011;38(4):389-94
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Muramatsu I. Pharmacological knockout of endothelin ET(A) receptors. Life Sci 2003;74(2-3):405-9
   PubMed Web of Science ®Google Scholar
• Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21(3):527-35
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao G, Fan H, et al. Mesenchymal stem cells ameliorate Th1-induced pre-eclampsia-like symptoms in mice via the suppression of TNF-alpha expression. PLoS One 2014;9(2):e88036
   PubMed Web of Science ®Google Scholar
• James JL, Srinivasan S, Alexander M, Chamley LW. Can we fix it? Evaluating the potential of placental stem cells for the treatment of pregnancy disorders. Placenta 2014;35(2):77-84
   PubMed Web of Science ®Google Scholar